Maas BiolAB, LLC Awarded Department Of Defense/DTRA Contract

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--The Defense Threat Reduction Agency (DTRA) has funded a Maas BiolAB, LLC research project to continue investigation of the neuroprotective properties of cyclosporin in models of chemical warfare agent exposure. The $117,000 award was made under the Chemical & Biological Defense Medical (CBM) Science & Technology (S&T) Extramural Program for further study of the brain penetration of cyclosporin and its effectiveness in protecting and prolonging the survival of mitochondria within brain tissue that has been exposed to nerve agents.